Loading…
NSE · Source: INVESTORGAIN
As disclosed by the issuer.
| KPI | Value | Period | Pages |
|---|---|---|---|
| Revenue from operations |
| 3,516.69 |
| three months ended June 30, 2026 |
| — |
| EBITDA | 485.76 | three months ended June 30, 2026 | — |
| Restated profit/(loss) after tax | 150.87 | three months ended June 30, 2026 | — |
| PAT margin | 4.29% | three months ended June 30, 2026 | — |
| Return on equity | 2.07% | three months ended June 30, 2026 | — |
| Net debt to EBITDA | 4.89 | three months ended June 30, 2026 | — |
Sahajanand Medical Technologies Limited is a Class III and Class C/D medical devices company founded in 2001, specializing in vascular and structural heart interventions. The company has a presence in 65 countries and has developed innovative products, including the Supraflex Cruz, a biodegradable polymer-based drug-eluting stent.
The Indian medical device industry is projected to grow significantly, reaching USD 50.1 billion by 2030, with a CAGR of 26.9%. The market is transitioning towards increased domestic production and exports, supported by government initiatives.